article thumbnail

Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling

Frontiers in Cardiovascular Medicine

ObjectiveClinical practice currently faces a significant shortfall in specific biomarkers needed for diagnosing right ventricular (RV) remodeling in patients with pulmonary hypertension (PH). MiRNA sequencing analyses revealed 19 dif-miRNAs (12 upregulated and 7 downregulated) between the two groups.

article thumbnail

Unveiling the threat of crystalline silica on the cardiovascular system. A comprehensive review of the current knowledge

Frontiers in Cardiovascular Medicine

Specific cardiovascular diseases, such as acute myocardial infarction, arrhythmias, pulmonary hypertension and pericarditis, were also pointed. Further studies are needed to identify specific/distinctive biomarkers to improve early detection of CVDs in silica exposed workers.

article thumbnail

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

DAIC

“This latest patent further secures the broad therapeutic potential of brilaroxazine for inflammatory conditions driven by underlying disruption in serotonin signaling like pulmonary hypertension,” said Laxminarayan Bhat, Ph.D. Founder, President, and CEO. Brilaroxazine has already received Orphan Drug Designation by the U.S.

Pulmonary 111
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Role of Inflammatory Biomarkers in Mediating Causal Effect of Life Course Body Composition on Hypertension

Hypertension Journal

Hypertension, Ahead of Print. BACKGROUND:The mediating role of inflammatory biomarkers in the causal relationship between body composition and hypertension remains unclear and requires further investigation.METHODS:This study used a combination of retrospective observational analysis and Mendelian randomization approaches.

article thumbnail

Metabolomic profiling reveals key metabolites associated with hypertension progression

Frontiers in Cardiovascular Medicine

Introduction Pre-hypertension is a prevalent condition among the adult population worldwide. It is characterized by asymptomatic elevations in blood pressure beyond normal levels but not yet reaching the threshold for hypertension. Objective The precise mechanisms driving the progression of hypertension remain unknown.

article thumbnail

Low diffusing capacity for carbon monoxide in chronic thromboembolic pulmonary hypertension: a biomarker for microvascular disease?

Heart BMJ

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complex pulmonary vascular disorder that involves major vessel and microvascular disease components. 1 2 Secondary microvasculopathy of CTEPH forms the pathophysiological basis for pulmonary hypertension-targeted medical therapies given for CTEPH.